Kongresser

Nyheter
Sykdommer
Kongresser
Samfunnet
ASCO
EHA

ASCO Antall artikler: 11

EHA Antall artikler: 8

Registrer deg for nyhetsbrev

For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.

Abonner på nyhetsbrev

For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.

Navn *

Please enter your name!

Email *

Please enter your email!

Yrkestittel *

Arbeidsplass *

Arbeidsplass

Sikkerhet *

Send me a copy

Nyheter fra ESMO

Long-Term Survival in a Significant Proportion of Patients with a 1p/19q Codeleted Anaplastic Oligodendroglioma Long-Term Survival in a Significant Proportion of Patients with a 1p/19q Codeleted Anaplastic Oligodendroglioma Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy

Created on: Jun 28, 2022 | 09:00 am

Jun 28, 2022 | 09:00 am
EMA Recommends Extension of Therapeutic Indications for Olaparib EMA Recommends Extension of Therapeutic Indications for Olaparib New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer

Created on: Jun 27, 2022 | 15:00 pm

Jun 27, 2022 | 15:00 pm
Age and Frailty Should Be Considered Independently When Evaluating Potential Risk for Side Effects Among Older Adults Treated with ICIs Age and Frailty Should Be Considered Independently When Evaluating Potential Risk for Side Effects Among Older Adults Treated with ICIs Findings from a population-level retrospective cohort study

Created on: Jun 27, 2022 | 09:00 am

Jun 27, 2022 | 09:00 am
FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma Evidence for efficacy is based on the results from the ELARA study

Created on: Jun 24, 2022 | 15:00 pm

Jun 24, 2022 | 15:00 pm
EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients The risk of ocular toxicity, including risk of severe visual loss and need for monitoring in paediatric patients treated with crizotinib

Created on: Jun 24, 2022 | 09:00 am

Jun 24, 2022 | 09:00 am

Powered by Warp Theme Framework

Nyheter
Sykdommer
Kongresser
Samfunnet
ASCO
EHA